These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 16522573)

  • 1. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In defence of priority review vouchers.
    Sonderholm J
    Bioethics; 2009 Sep; 23(7):413-20. PubMed ID: 19659848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
    Ridley DB; Sánchez AC
    Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliminating neglected diseases: impact of published paper.
    Brownback S
    Health Aff (Millwood); 2007; 26(5):1509. PubMed ID: 17848471
    [No Abstract]   [Full Text] [Related]  

  • 5. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA review vouchers.
    Moe J; Grabowski H; Ridley D
    N Engl J Med; 2009 Feb; 360(8):837; author reply 837-8. PubMed ID: 19228632
    [No Abstract]   [Full Text] [Related]  

  • 9. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we help one billion sick people?
    Maliski E; Gund P; Brown F
    Curr Opin Drug Discov Devel; 2008 May; 11(3):301-2. PubMed ID: 18428082
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 14. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.
    Sachs-Barrable K; Conway J; Gershkovich P; Ibrahim F; Wasan KM
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1429-34. PubMed ID: 24512098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
    Daly R
    Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.